Levodopa-induced dyskinesias in Parkinson's disease

Handbook of Clinical Neurology

Volumn 84, Issue , 2007, Pages 185-218

  Obeso, Jose A ^a   Merello, Marcelo ^b   Rodríguez Oroz, Maria C ^a   Marin, Concepció ^c   Guridi, Jorge ^a   Alvarez, Lazaro ^d  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

^b Instituto de Investigaciones Neurologicas Raul Carrera   (Argentina)

^c HOSPITAL CLÍNIC   (Spain)

^d CENTRO INTERNACIONAL DE RESTAURACIÓN NEUROLÓGICA CIREN   (Cuba)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 67649548342     PISSN: 00729752     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0072-9752(07)84040-1     Document Type: Chapter

References (301)

1. Albin R.L., Young A.B., and Penney J.B. The functional anatomy of basal ganglia disorders. Trends Neurosci 12 (1989) 366-375
2. Alkhani A., and Lozano A.M. Pallidotomy for Parkinson's disease: a review of contemporary literature. J Neurosurg 94 (2001) 43-49
3. Alonso-Frech F., Zamarbide I., Alegre M., et al. Slow oscillatory activity and levodopa-induced dyskinesias in Parkinson's disease. Brain 129 (2006) 1748-1757
4. Alvarez L., Macias R., Guridi J., et al. Dorsal subthalamotomy for Parkinson's disease. Mov Disord 16 (2001) 72-78
5. Alvarez L., Macias R., Lopez G., et al. Bilateral subthalamotomy in Parkinson's disease: initial and long term response. Brain 128 (2005) 570-583
6. Andersson M., Hilbertson A., and Cenci M.A. Striatal fosB expression is causally linked with L-Dopa-induced abnormal involuntary movements and the associates upregulation of striatal prodynorphin mRNA in a rat model of Parkinson's disease. Neurobiol Dis 6 (1999) 461-474
7. Anglade P., Mouatt-Pringent A., Agid Y., et al. Synaptic plasticity in the caudate nucleus of patients with Parkinson's disease. Neurodegeneration 5 (1996) 121-128
8. Antonelli T., Fuxe K., Tomasini M.C., et al. Effects of sarizotan on the corticostriatal glutamate pathways. Synapse 58 (2005) 193-199
9. Asselin M.C., Soghomonian J.J., Cote P.Y., et al. Striatal changes in preproenkephalin mRNA levels in parkinsonian monkeys. Neuroreport 5 (1994) 2137-2140
10. Aubert I., Guigoni C., Hakansson K., et al. Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia. Ann Neurol 57 (2005) 17-26
11. Augood S.J., Emson P.C., Mitchell I.J., et al. Cellular localisation of enkephalin gene expression in MPTP-treated cynomolgus monkeys. Brain Res Mol Brain Res 6 (1989) 85-92
12. Bakay R., DeLong M.R., and Vitek J.L. Posteroventral pallidotomy for Parkinson's disease. Letter. J Neurosurg 77 (1992) 487-488
13. Bara-Jimenez W., Bibbiani F., Morris M.J., et al. Effects of serotonin 5-HT1A agonist in advanced Parkinson's disease. Mov Disord 20 (2005) 932-936
14. Barbeau A. Pathophysiology of the oscillations in performance after long-term therapy with L-DOPA. In: Birkmayer W., and Hornykiewicz O. (Eds). Advances in Parkinsonism (1976), Roche Editions, Basel. 424-428
15. Baron M.S., Vitek J.L., Bakay R., et al. Treatment of advanced Parkinson's disease by unilateral posterior GPi pallidotomy: 4 years results of a pilot study. Mov Disord 15 (2000) 230-237
16. Bartoszyk G.D., van Amsterdam C., Greiner H.E., et al. Sarizotan, a serotonin 5-HT1A receptor agonist and dopamine receptor ligand 1. Neurochemical profile. J Neural Transm 111 (2004) 113-126
17. Bejjani B., Damier P., Arnoulf I., et al. Pallidal stimulation for Parkinson's disease. Two targets?. Neurology 49 (1997) 1564-1569
18. Bejjani B., Gervais D., Arnulf I., et al. Axial parkinsonian symptoms can be improved: the role of levodopa and bilateral subthalamic stimulation. J Neurol Neurosurg Psychiatry 68 (2000) 595-600
19. Belanger N., Gregoire L., Hadj Tahar A., et al. Chronic treatment with small doses of cabergoline prevents dopa-induced dyskinesias in parkinsonian monkeys. Mov Disord 18 (2003) 1436-1441
20. Bellforte J.E., and Pazo J.H. Turning behaviour induced by stimulation of the 5-HT receptors in the subthalamic nucleus. Eur J Neurosci 19 (2004) 346-355
21. Benabid A.L., Pollak P., Hommel M., et al. Traitement du tremblement parkinsonien par stimulation chronique du noyau ventral intermédiere du thalamus. Rev Neurol 145 (1989) 320-323
22. Benabid A.L., Pollak P., Gao J.M., et al. Chronic electrical stimulation of the ventralis intermedius nucleus of the thalamus as a treatment of movement disorders. J Neurosurg 84 (1996) 203-214
23. Bergman H., Wichmann T., Karmon B., et al. The primate subthalamic nucleus. II. Neuronal activity in the MPTP model of parkinsonism. J Neurophysiol 72 (1994) 507-520
24. Betarbet R., Poisik O., Sherer T.B., et al. Differential expression and ser897 phosphorylation of striatal N-methyl-d-aspartate receptor subunit NR1 in animal models of Parkinson's disease. Exp Neurol 187 (2004) 76-85
25. Bezard E., Brotchie J.M., and Gross C.E. Pathophysiology of levodopa-induced dyskinesia: potential for new therapies. Nat Rev Neurosci 2 (2001) 577-588
26. Bezard E., Ferry S., Mach U., et al. Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function. Nat Med 9 (2003) 762-767
27. Bibbiani F., Oh J.O., and Chase T.N. Serotonin 5-HT1A improves motor complications in rodent and primate parkinsonian models. Neurology 57 (2001) 1829-1834
28. Blanchet P.J., Boucher R., and Bedard P.J. Excitotoxic lateral pallidotomy does not relieve L-dopa-induced dyskinesia in MPTP parkinsonian monkeys. Brain Res 65 (1994) 32-39
29. Blanchet P.J., Konitsiotis S., Whittemore E.R., et al. Diiffering effects of N-methyl-D-aspartate-receptor subtype selective antagonists on dyskinesias in levodopa-treated 1-methyl-4-phenyl-tetrahydropyridine monkeys. J Pharmacol Exp Ther 290 (1999) 1034-1040
30. Blandini F., Garcia-Osuna M., and Greenamyre J.T. Subthalamic ablation reverses changes in basal ganglio oxidative metabolism and motor response to apomorphine induced by nigrostriatal lesion in rats. Eur J Neurosci 9 (1997) 1407-1413
31. Boraud T., Bezard E., Guehl D., et al. Effects of L-DOPA on neuronal activity of the globus pallidus externalis (GPe) and globus pallidus internalis (GPi) in the MPTP-treated monkey. Brain Res 787 (1998) 157-160
32. Bonifati V., Fabrizio E., Cipriani R., et al. Buspirone in levodopa-induced dyskinesias. Clin Neuropharmacol 17 (1994) 73-82
33. Boraud T., Bezard E., Bioulac B., et al. Dopamine agonist-induced dyskinesias are correlated to both firing pattern and frequency alterations of pallidal neurones in the MPTP-treated monkey. Brain 124 (2001) 546-557
34. Bordet R., Ridray S., Carboni S., et al. Induction of dopamine D3 receptor expression as a mechanism of behavioral sensitization to levodopa. Proc Natl Acad Sci USA 94 (1997) 3363-3367
35. Bordet R., Ridray S., Schwartz J.C., et al. Involvement of the direct striatonigral pathway in levodopa-induced sensitization in 6-hydroxydopamine-lesioned rats. Eur J Neurosci 12 (2000) 2117-2123
36. Bove J., Serrats J., Mengod G., et al. Neuroprotection induced by the adenosine A (2A) antagonist CSC in the 6-OHDA rat model of parkinsonism: effect on the activity of striatal output pathways. Exp Brain Res 165 (2005) 362-374
37. Bracco F., Battaglia A., Chouza C., et al. PKDS009 Study Group. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study. CNS Drugs 18 (2004) 733-746
38. Braz C.A., Borges V., and Ferraz H.B. Effect of riluzole on dyskinesia and duration of the on state in Parkinson disease patients: a double-blind, placebo-controlled pilot study. Clin Neuropharmacol 27 (2004) 25-29
39. Bronstein J.M., DeSalles A., and DeLong M.R. for the Workshop Participants. Stereotactic pallidotomy in the treatment of Parkinson's disease. Arch Neurol 56 (1999) 1064-1069
40. Brooks D.J., Ibanez V., Sawle G.V., et al. Striatal D-2 receptor status in patients with Parkinson's disease, striatonigral degeneration, and progressive supranuclear palsy, measured with 11C-raclopride and positron emission tomography. Ann Neurol 31 (1992) 184-192
41. Brooks D.J., Piccini P., Turjanski N., et al. Neuroimaging of dyskinesia. Ann Neurol 47 Suppl 1 (2000) S154-S158
42. Brotchie J.M., Lee J., and Venderova K. Levodopa-induced dyskinesia in Parkinson's disease. J Neural Transm 112 (2005) 359-391
43. Brotchie P., Iansek R., and Horne M.K. Motor function of the monkey globus pallidus. 2. Cognitive aspects of movement and phasic neuronal activity. Brain 114 (1991) 1685-1702
44. Brown P. Oscillatory nature of human basal ganglia activity: relationship to the pathophysiology of Parkinson's disease. Mov Disord 18 (2003) 357-363
45. Burbaud P., Bonnet B., Guehl D., et al. Movement disorders induced by gamma-aminobutyric agonist and antagonist injections into the internal globus pallidus and substantia nigra pars reticulata of the monkey. Brain Res 780 (1998) 102-107
46. Burchiel K., Anderson V., Favre J., et al. Comparison of pallidal and subthalamic nucleus deep brain stimulation for advanced Parkinson's disease: results of a randomized, blinded pilot study. Neurosurgery 45 (1999) 1375-1384
47. Calabresi P., Mercuri N.B., Sancesario G., et al. Electrophysiology of dopamine-denervated striatal neurons. Implications for Parkinson's disease. Brain 116 (1993) 433-452
48. Calabresi P., Pisani A., Mercuri N.B., et al. The corticostriatal projection: from synaptic plasticity to dysfunctions of the basal ganglia. Trends Neurosci 19 (1996) 19-24
49. Calabresi P., Giacomini P., Centonze D., et al. Levodopa-induced dyskinesia: a pathological form of striatal synaptic plasticity?. Ann Neurol 47 (2000) S60-S68
50. Calon F., and Di Paolo T. Levodopa response motor complications-GABA receptors and preproenkephalin expression in human brain. Parkinsonism Relat Disord 8 (2002) 449-454
51. Calon F., Goulet M., Blanchet P.J., et al. Levodopa or D2 agonist induced dyskinesia in MPTP monkeys: correlation with changes in dopamine and GABA-A receptors in the striatopallidal complex. Brain Res 680 (1995) 43-52
52. Calon F., Morissette M., Goulet M., et al. Chronic D1 and D2 dopaminomimetic treatment of MPTP-denervated monkeys: effects on basal ganglia GABA(A)/benzodiazepine receptor complex and GABA content. Neurochem Int 35 (1999) 81-91
53. Calon F., Hadj Tahar A., Blanchet P.J., et al. Dopamine-receptor stimulation: behavioral and biochemical consequences. Trends Neurosci 23 Suppl (2000) S92-S100
54. Calon F., Morissette M., Ghribi O., et al. .Alteration of glutamate receptors in the striatum of dyskinetic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys following dopamine agonist treatment. Prog Neuropsychopharmacol Biol Psychiatry 26 (2002) 127-138
55. Calon F., Rajput A.H., Hornykiewicz O., et al. Levodopa-induced motor complications are associated with alterations of glutamate receptors in Parkinson's disease. Neurobiol Dis 14 (2003) 404-416
56. Calon F., Morissette M., Rajput A.H., et al. Changes of GABA receptors and dopamine turnover in the postmortem brains of parkinsonians with levodopa-induced motor complications. Mov Disord 18 (2003) 241-253
57. Calon F., Dridi M., Hornykiewicz O., et al. Increased adenosine A2A receptors in the brain of Parkinson's disease patients with dyskinesias. Brain 127 (2004) 1075-1084
58. Caparros-Lefebre D., Blond S., Feltin M., et al. Improvement of levodopa induced dyskinesias by thalamic deep brain stimulation is related to slight variation in electrode placement: possible involvement of the center median and parafascicular complex. J Neurol Neurosurg Psychiatry 67 (1999) 308-314
59. Carpenter M.B., Witthier J.R., and Mettler F.A. Analysis of choreoid hyperkinesias in the rhesus monkey. J Comp Neurol 92 (1950) 293-322
60. Carpentier A.F., Bonnet A.M., Vidailhet M., et al. Improvement of levodopa-induced dyskinesia by propranolol in Parkinson's disease. Neurology 46 (1996) 1548-1551
61. Carroll C.B., Bain P.G., Teare L., et al. Cannabis for dyskinesia in Parkinson disease: a randomized double-blind crossover study. Neurology 63 (2004) 1245-1250
62. Carta A.R., Pinna A., Cauli O., et al. Differential regulation of GAD67, enkephalin and dynorphin mRNAs by chronic-intermittent L-dopa and A2A receptor blockade plus L-dopa in dopamine-denervated rats. Synapse 44 (2002) 166-174
63. Carvalho A.L., Duarte C.B., and Carvalho A.P. Regulation of AMPA receptors by phosphorylation. Neurochem Res 25 (2000) 1245-1255
64. Cenci M.A. Transcription factors involved in the pathogenesis of L-DOPA-induced dyskinesia in a rat model of Parkinson's disease. Amino Acids 23 (2002) 105-109
65. Cenci M.A., Lee C.S., and Bjorklund A. L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA. Eur J Neurosci 10 (1998) 2694-2706
66. Centonze D., Calabresi P., Giacomini P., et al. Neurophysiology of Parkinson's disease: from basic research to clinical correlates. Clin Neurophysiol 110 (1999) 2006-2013
67. Centonze D., Gubellini P., Rossi S., et al. Subthalamic nucleus lesions reverses motor abnormalities and striatal glutamatergic overactivity in experimental parkinsonism. Neuroscience 133 (2005) 831-840
68. Chapuis S., Ouchchane L., Metz O., et al. Impact of the motor complications of Parkinson's disease on the quality of life. Mov Disord 20 (2005) 224-230
69. Chase T.N., and Oh J.D. Striatal dopamine- and glutamate-mediated dysregulation in experimental parkinsonism. Trends Neurosci 23 10 Suppl (2000) S86-S91
70. Chase T.N., Baronti F., Fabbrini G., et al. Rationale for continuous dopaminomimetic therapy of Parkinson's disease. Neurology 39 Suppl 2 (1989) 7-10
71. Chase T.N., Oh J.D., and Konitsiotis S. Antiparkinsonian and antidyskinetic activity of drugs targeting central glutamatergic mechanisms. J Neurol 247 Suppl 2 (2000) 1136-1142
72. Chen C.C., Lee S.T., Wu T., et al. Hemiballism after subthalamotomy in patients with Parkinson's disease: report of 2 cases. Mov Disord 17 (2002) 1367-1371
73. Cooper I.S. Hemiballismus and hemichorea. In: Cooper I.S. (Ed). The Vital Probe: My life as a brain surgeon (1969), Morton and Company, New York 293-315
74. Cotzias G.C., Papavasiliou P.S., and Gellene R. Modification of parkinsonism-chronic treatment with L-dopa. N Engl J Med 280 (1969) 337-345
75. Crosby N.J., Deane K.H., and Clarke C.E. Amantadine for dyskinesia in Parkinson's disease. Cochrane Database Syst Rev (2003) CD003467
76. Crossman A.R. Primate models of dyskinesia: the experimental approach to the study of basal ganglia-related involuntary movement disorders. Neuroscience 21 (1987) 1-40
77. Crossman A.R. A hypothesis on the pathophysiological mechanisms that underlie levodopa- or dopamine agonist-induced dyskinesia in Parkinson's disease: implications for future strategies in treatment. Mov Disord 5 (1990) 100-108
78. Crossman A.R., Mitchell I.J., Sambrook M.A., et al. Chorea and myoclonus in the monkey induced by gamma-aminobutyric acid antagonist in the lentiform complex: the site of drug action and a hypothesis for the neural mechanism of chorea. Brain 111 (1988) 1211-1233
79. de la Fuente-Fernandez R., Sossi V., Huang Z., et al. Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias. Brain 127 (2004) 2747-2754
80. Del Dotto P., Pavese N., Gambaccini G., et al. Intravenous amantadine improves levadopa-induced dyskinesias: an acute double-blind placebo-controlled study. Mov Disord 16 (2001) 515-520
81. Delfs J.M., Vivian M., Ciaramitaro M., et al. Subthalamic nucleus lesions. Widespread effects on changes in gene expression induced by nigrostriatal dopamine depletion in rats. J Neurosci 15 (1995) 6562-6575
82. DeLong M.R. Primate models of movement disorders of basal ganglia origin. Trends Neurosci 13 (1990) 281-285
83. Denny-Brown D., and Yanagisawa N. The role of the basal ganglia in the initiation of movement. Res Publ Assoc Res Nerv Ment Dis 55 (1976) 115-149
84. Derome P.J., Jedynak C.D., Visot A., et al. Traitement des mouvements anormaux par lésions thalamiques. Rev Neurol 142 (1986) 391-397
85. Dingledine R., Borges K., Bowie D., et al. The glutamate receptor ion channels. Pharmacol Rev 51 (1999) 7-61
86. Doucet J.P., Nakabeppu Y., Bedard P.J., et al. Chronic alterations in dopaminergic neurotransmission produce a persistent elevation of deltaFosB-like protein(s) in both the rodent and primate striatum. Eur J Neurosci 8 (1996) 365-381
87. Dunah A.W., and Standaert D.G. Dopamine D1 receptor-dependent trafficking of striatal NMDA glutamate receptors to the postsynaptic membrane. J Neurosci 21 (2001) 5546-5558
88. Dunah A.W., Wang Y., Yasuda R.P., et al. Alterations in subunit expression, composition, and phosphorylation of striatal N-methyl-D-aspartate glutamate receptors in a rat 6-hydroxydopamine model of Parkinson's disease. Mol Pharmacol 57 (2000) 342-352
89. Dunah A.W., Sirianni A.C., Fienberg A.A., et al. Dopamine D1-dependent trafficking of striatal N-methyl-D-aspartate glutamate receptors requires Fyn protein tyrosine kinase but not DARPP-32. Mol Pharmacol 65 (2004) 121-129
90. Durif F., Vidailhet M., Bonnet A.M., et al. Levodopa-induced dyskinesias are improved by fluoxetine. Neurology 45 (1995) 1855-1858
91. Durif F., Debilly B., Galitzky M., et al. Clozapine improves dyskinesias in Parkinson disease: a double-blind, placebo-controlled study. Neurology 62 (2004) 381-388
92. Eidelberg D., Moeller J.R., Ishikawa T., et al. Regional metabolic correlates of surgical outcome following unilateral pallidotomy for Parkinson's disease. Ann Neurol 39 (1996) 450-459
93. Fahn S. The spectrum of levodopa-induced dyskinesias. Ann Neurol 47 Suppl 1 (2000) 2-11
94. Favre J., Burchiel K.J., Taha J.M., et al. Outcome of unilateral and bilateral pallidotomy for Parkinson's disease: patient assessment. Neurosurgery 46 (2000) 344-355
95. Filion M., and Tremblay L. Abnormal spontaneous activity of globus pallidus neurons in monkeys with MPTP-induced parkinsonism. Brain Res 547 (1991) 142-151
96. Filion M., Treblay L., and Bedard P.J. Effects of dopamine agonist on the spontaneous activity of the globus pallidus neurons in monkeys with MPTP-induced parkinsonism. Brain Res 547 (1991) 152-161
97. Foffani G., Ardolino G., Meda B., et al. Altered subthalamo-pallidal synchronisation in parkinsonian dyskinesias. J Neurol Neurosurg Psychiatry 76 (2005) 426-428
98. Ford B., Winfield L., Pullman S.L., et al. Subthalamic nucleus stimulation in advanced Parkinson's disease: blinded assessment at one year follow up. J Neurol Neurosurg Psychiatry 75 (2004) 1255-1259
99. Fox M.W., Ahlskog J.E., and Kelly P.J. Stereotactic ventrolateralis thalamotomy for medically refractory tremor in post-levodopa era Parkinson's disease patients. J Neurosurg 75 (1991) 723-730
100. Francois C., Savy C., Jan C., et al. Dopaminergic innervation of the subthalamic nucleus in the normal state, in MPTP-treated monkeys, and in Parkinson's disease patients. J Comp Neurol 425 (2000) 121-129
101. Freed C.R., Greene P.E., Breeze R.E., et al. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med 344 (2001) 710-719
102. Genderman G.L., Ronesi J., and Lovinger D.M. Postsynaptic endocannabinoid release is critical to long-term depression in the striatum. Nat Neurosci 5 (2002) 445-451
103. Gerfen C.R. Molecular effects of dopamine on striatal projections pathways. Trends Neurosci 23 (1995) S64-S70
104. Gerfen C.R., Engber T.M., Mahan L.C., et al. D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science 250 (1990) 1429-1432
105. Ghika J., Villemure J., Fankhauser H., et al. Efficiency and safety of bilateral contemporaneous pallidal stimulation (deep brain stimulation) in levodopa-responsive patients with Parkinson's disease with severe fluctuations: a 2-year follow-up review. J Neurosurg 89 (1998) 713-718
106. Grabli D., McCairn K., Hirsch E.C., et al. Behavioural disorders induced by external globus pallidus dysfunction in primates: I. Behavioural study. Brain 127 (2004) 2039-2054
107. Graham W.C., Sambrook M.A., and Crossman A.R. Differential effect of chronic dopaminergic treatment on dopamine D1 and D2 receptors in the monkey brain in MPTP-induced parkinsonism. Brain Res 602 (1993) 290-303
108. Grondin R., Bedard P.J., Hadj Tahar A., et al. Antiparkinsonian effect of a new selective adenosine A2A receptor antagonist in MPTP-treated monkeys. Neurology 52 (1999) 1673-1677
109. Grondin R., Hadj Tahar A., Doan V.D., et al. Noradrenoceptor antagonism with idazoxan improves L-dopa-induced dyskinesias in MPTP monkeys. Naunyn Schmiedebergs Arch Pharmacol 361 (2000) 181-186
110. Gubellini P., Pisani A., Centonze D., et al. Metabotropic glutamate receptors and striatal synaptic plasticity: implications for neurological diseases. Prog Neurobiol 74 (2004) 271-300
111. Guigoni C., Dovero S., Aubert I., et al. Levodopa-induced dyskinesia in MPTP-treated macaques is not dependent on the extent and pattern of nigrostriatal lesioning. Eur J Neurosci 22 (2005) 283-287
112. Guigoni C., Li Q., Aubert I., et al. Involvement of sensorimotor, limbic, and associative basal ganglia domains in L-3,4-dihydroxyphenylalanine-induced dyskinesia. J Neurosci 25 (2005) 2102-2107
113. Guridi J., and Obeso J.A. The subthalamic nucleus, hemiballismus and Parkinson's disease: reappraisal of a surgical dogma. Brain 124 (2001) 5-19
114. Guridi J., Luquin M.R., Herrero M.T., et al. The subthalamic nucleus: a possible target for stereotaxic surgery in Parkinson's disease. Mov Disord 8 (1993) 421-429
115. Guridi J., Herrero M.T., Luquin M.R., et al. Subthalamotomy in parkinsonian monkeys. Behavioural and biochemical analysis. Brain 119 (1996) 1717-1727
116. Hadj Tahar A., Gregoire L., Darre A., et al. Effect of a selective glutamate antagonist on L-dopa-induced dyskinesias in drug-naive parkinsonian monkeys. Neurobiol Dis 15 (2004) 171-176
117. Hallett P.J., Dunah A.W., Ravenscroft P., et al. Alterations of striatal NMDA receptor subunits associated with the development of dyskinesia in the MPTP-lesioned primate model of Parkinson's disease. Neuropharmacology 48 (2005) 503-516
118. Hamada I., and DeLong M.R. Excitotoxic acid lesions of the primate subthalamic nucleus result in transient dyskinesias of the contralateral limbs. J Neurophysiol 68 (1992) 1850-1858
119. Hamani C., Richter E., Schwalb J., et al. Bilateral subthalamic nucleus stimulation for Parkinson's disease: a systematic review of the clinical literature. Neurosurgery 56 (2005) 1313-1324
120. Hamel W., Fietzek U., Morsnowski A., et al. Deep brain stimulation of the subthalamic nucleus in Parkinson's disease: evaluation of active electrode contacts. J Neurol Neurosurg Psychiatry 74 (2003) 1036-1046
121. Hassler R. Striatal control of locomotion, intentional actions and of integrating and perceptive activity. J Neurol Sci 36 (1978) 187-224
122. Hassler R., and Riechert T. Indikationen und lokalisations methode der gezieten hirnoperationen. Nervenarzt 25 (1954) 441-447
123. Hassler R., Riechert T., Mundinger F., et al. Physiological observations in stereotaxic operations in extrapyramidal motor disturbances. Brain 83 (1960) 337-349
124. Hedreen J.C. Tyrosine hydroxylase-immunoreactive elements in the human globus pallidus and subthalamic nucleus. J Comp Neurol 409 (1999) 400-410
125. Henry B., Crossman A.R., and Brotchie J.M. Effect of repeated L-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat. Exp Neurol 155 (1999) 204-220
126. Henry B., Fox S.H., Crossman A.R., et al. Mu- and delta-opioid receptor antagonists reduce levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease. Exp Neurol 171 (2001) 139-146
127. Henry B., Duty S., Fox S.H., et al. Increased striatal pre-proenkephalin B expression is associated with dyskinesia in Parkinson's disease. Exp Neurol 183 (2003) 458-468
128. Herrero M.T., Augood S.J., Hirsch E.C., et al. Effects of L-DOPA on preproenkephalin and preprotachykinin gene expression in the MPTP-treated monkey striatum. Neuroscience 68 (1995) 1189-1198
129. Herrero M.T., Augood S.J., Asensi H., et al. Effects of L-dopa therapy on dopamine D-2 receptor mRNA expression in the striatum of MPTP-intoxicated parkinsonian monkeys. Brain Res Mol Brain Res 42 (1996) 149-155
130. Herrero M.T., Levy R., Ruberg M., et al. Consequence of nigrostriatal denervation and L-dopa therapy on the expression of glutamic acid decarboxylase messenger RNA in the pallidum. Neurology 47 (1996) 219-224
131. Hershey T., Black K.J., Stambuk M.K., et al. Altered thalamic response to levodopa in Parkinson's patients with dopa-induced dyskinesias. Proc Natl Acad Sci USA 95 (1998) 12016-12021
132. Herzog J., Volkmann J., Krack P., et al. Two-year follow-up of subthalamic deep brain stimulation in Parkinson's disease. Mov Disord 18 (2003) 1332-1337
133. Hikosaka O., and Wurtz R.H. Visual and oculomotor functions of monkey substantia nigra pars reticulata. I. Relation of visual and auditory responses to saccades. J Neurophysiol 49 (1983) 1230-1253
134. Hirsch E., Périer C., Orieux G., et al. Metabolic effects of nigrostriatal denervation in basal ganglia. Trends Neurosci 23 Suppl (2000) 78-85
135. Hollmann M., and Heinemann S. Cloned glutamate receptors. Annu Rev Neurosci 17 (1994) 31-108
136. Holloway R.G., Shoulson I., Fahn S., et al. Parkinson Study Group Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol 61 (2004) 1044-1053
137. Horak F.B., and Anderson M.E. Influence of globus pallidus on arm movements in monkeys. I. Effects of kainic acid-induced lesions. J Neurophysiol 52 (1984) 290-304
138. Horowski R., Marsden C.D., and Obeso J.A. Continuous dopaminergic stimulation for Parkinson's disease: state of the art and outlook. J Neural Trans 27 Suppl (1988) 249-252
139. Houeto J.L., Damier P., Bejjani P.B., et al. Suthalamic stimulation in Parkinson disease. A multidisciplinary approach. Arch Neurol 57 (2000) 461-465
140. Hoyer D., Hannon J.P., and Martin G.R. Molecular, pharmacological and functional diversity of 5-HT receptors. Pharmacol Biochem Behav 71 (2002) 533-554
141. Hsu A., Togasaki D.M., Bezard E., et al. Effect of the D3 dopamine receptor partial agonist BP897 [N-[4-(4-(2-methoxyphenyl)piperazinyl)butyl]-2-naphthamide] on L-3,4-dihydroxyphenylalanine-induced dyskinesias and parkinsonism in squirrel monkeys. J Pharmacol Exp Ther 311 (2004) 770-777
142. Hurley M.J., Jolkkonen J., Stubbs C.M., et al. Dopamine D3 receptors in the basal ganglia of the common marmoset and following MPTP and L-DOPA treatment. Brain Res 709 (1996) 259-264
143. Hurley M.J., Stubbs C.M., Jenner P., et al. D3 receptor expression within the basal ganglia is not affected by Parkinson's disease. Neurosci Lett 214 (1996) 75-78
144. Inase M., Buford J.A., and Anderson M.E. Changes in the control of arm position, movement, and thalamic discharge during local inactivation in the globus pallidus of the monkey. J Neurophysiol 75 (1996) 1087-1104
145. Intemann P.M., Masterman D., Subamanian I., et al. Staged bilateral pallidotomy for treatment of Parkinson disease. J Neurosurg 94 (2001) 437-444
146. Inzelberg R., Schechtman E., and Nisipeanu P. Cabergoline, pramipexole and ropinirole used as monotherapy in early Parkinson's disease: an evidence-based comparison. Drugs Aging 20 (2003) 847-855
147. Jacobs B.L., and Fornal C.A. 5-HT and motor control: a hypothesis. Trends Neurosci 16 (1993) 346-352
148. Jan C., Francois C., Tande D., et al. Dopaminergic innervation of the pallidum in the normal state, in MPTP-treated monkeys and in parkinsonian patients. Eur J Neurosci 12 (2000) 4525-4535
149. Jankovic J., Cardoso F., Grossman R.G., et al. Outcome after stereotactic thalamotomy for parkinsonism, essential, and others types of tremor. Neurosurgery 37 (1995) 680-687
150. Kaelin-Lang A., Liniger P., Probst A., et al. Adenosine A2A receptor gene expression in the normal striatum and after 6-OH-dopamine lesion. J Neural Transm 107 (2000) 851-859
151. Kanda T., Jackson M.J., Smith L.A., et al. Adenosine A2A antagonist: a novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys. Ann Neurol 43 (1998) 507-513
152. Kanda T., Jackson M.J., Smith L.A., et al. Combined use of the adenosine A (2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys. Exp Neurol 162 (2000) 321-327
153. Kannari K., Yamato H., Shen H., et al. Activation of 5-HT1A, but not 5-HT1 B receptors attenuates an increase in extracellular dopamine derived from exogenously administered L-Dopa in the striatum with nigrostriatal denervation. J Neurochem 76 (2001) 1346-1353
154. Kato M., and Kimura M. Effects of reversible blockade of basal ganglia on a voluntary arm movement. J Neurophysiol 68 (1992) 1516-1534
155. Katzenschlager R., Hughes A., Evans A., et al. Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: a prospective study using single-dose challenges. Mov Disord 20 (2005) 151-157
156. Kelly P.J., and Gillingham F.J. The long term of stereotaxic surgery and L-Dopa therapy in patients with Parkinson's disease. J Neurosurg 53 (1980) 332-337
157. Kim J.S., Lee K.S., Lee K.H., et al. Evidence of thalamic disinhibition in patients with hemichorea: semiquantitative analysis using SPECT. J Neurol Neurosurg Psychiatry 72 (2002) 329-333
158. Kleedorfer B., Lees A.J., and Stern G.M. Buspirone in the treatment of levodopa induced dyskinesias. J Neurol Neurosurg Psychiatry 54 (1991) 376-377
159. Kleiner-Fisman, Fisman D., Sime E., et al. Long-term follow-up of bilateral deep brain stimulation of the subthalamic nucleus in patients with advanced Parkinson's disease. J Neurosurg 99 (2003) 489-495
160. Konitsiotis S., Blanchet P.J., Verhagen L., et al. AMPA receptor blockade improves levodopa-induced dyskinesia in MPTP monkeys. Neurology 54 (2000) 1589-1595
161. Krack P., Pollak P., Limousin P., et al. Opposite motor effects of pallidal stimulation in Parkinson's disease. Ann Neurol 43 (1998) 180-192
162. Krack P., Pollak P., Limousin P., et al. From off period dystonia to peak dose chorea: the clinical spectrum of varying subthalamic nucleus activity. Brain 122 (1999) 1133-1146
163. Krack P., Batir A., Van Blercom N., et al. Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease. N Eng J Med 349 (2003) 1925-1934
164. Laitinen L.V., Bergerheim T., and Hariz M.I. Leksell's posteroventral pallidotomy in the treatment of Parkinson's disease. J Neurosurg 76 (1992) 53-61
165. Lang A.E., Lozano A.M., Montgomery E., et al. Posteroventral pallidotomy in advanced Parkinson's disease. N Engl J Med 337 (1997) 1036-1042
166. Lange K.W., Kornhuber J., and Riederer P. Dopamine/glutamate interactions in Parkinson's disease. Neurosci Biobehav Rev 21 (1997) 393-400
167. Lee T., Seeman P., Rajput A., et al. Receptor basis for dopaminergic supersensitivity in Parkinson's disease. Nature 273 (1978) 59-61
168. Levesque M., and Parent A. The striatofugal fiber system in primates: a reevaluation of its organization based on single-axon tracing studies. Proc Natl Acad Sci USA 102 (2005) 1888-1893
169. Levesque D., Martres M.P., Diaz J., et al. A paradoxical regulation of the dopamine D3 receptor expression suggests the involvement of an anterograde factor from dopamine neurons. Proc Natl Acad Sci USA 92 (1995) 1719-1723
170. Levy R., Dostrovsky J.O., Lang A.E., et al. Effects of apomorphine on subthalamic nucleus and globus pallidus internus neurons in patients with Parkinson's disease. J Neurophysiol 86 (2001) 249-260
171. Levy R., Ashby P., Hutchison W.D., et al. Dependence of subthalamic nucleus oscillations on movement and dopamine in Parkinson's disease. Brain 125 (2002) 1196-1209
172. Lieberman J.A. Dopamine partial agonists: a new class of antipsychotic. CNS Drugs 18 (2004) 251-267
173. Limousin P., Speelman J.D., Gielen F., et al. study collaborators. Multicentre European study of thalamic stimulation in parkinsonian and essential tremor. J Neurol Neurosurg Psychiatry 66 (1999) 289-296
174. Lindefors N., and Ungerstedt U. Bilateral regulation of glutamate tissue and extracellular levels in caudate-putamen by midbrain dopamine neurons. Neurosci Lett 115 (1990) 248-252
175. Liu X., Ford-Dunn H.L., Hayward G.N., et al. The oscillatory activity in the parkinsonian subthalamic nucleus investigated using the macro-electrodes for deep brain stimulation. Clin Neurophysiol 113 (2002) 1667-1672
176. Loher T., Burgunder J.M., Pohle T., et al. Long-term pallidal deep brain stimulation in patients with advanced Parkinson's disease: 1-year follow-up study. J Neurosurg 96 (2002) 844-853
177. Lokk J. Memantine can relieve certain symptoms in Parkinson disease. Improvement achieved in two out of three described cases with dyskinesia and cognitive failure. Lakartidningen 101 (2004) 2003-2006
178. Lozano A.M. The subthalamic nucleus: myth and opportunities. Mov Disord 16 (2001) 183-184
179. Lozano A.M., Lang A.E., Levy R., et al. Neuronal recordings in Parkinson's disease patients with dyskinesias induced by apomorphine. Ann Neurol 47 4 Suppl 1 (2000) S141-S146
180. Luginger E., Wenning G.K., Bosch S., et al. Beneficial effects of amantadine on L-dopa-induced dyskinesias in Parkinson's disease. Mov Disord 15 (2000) 873-878
181. Lundblad M., Vaudano E., and Cenci M.A. Cellular and behavioural effects of the adenosine A2a receptor antagonist KW-6002 in a rat model of l-DOPA-induced dyskinesia. J Neurochem 84 (2003) 1398-1410
182. Luquin M.R., Laguna J., and Obeso J.A. Selective D2 receptor stimulation induces dyskinesia in parkinsonian monkeys. Ann Neurol 31 (1992) 551-554
183. Luquin M.R., Scipioni O., Vaamonde J., et al. Levodopa-induced dyskinesias in Parkinson's disease. Clinical and pharmacological classification. Mov Disord 7 (1992) 117-124
184. Ma Y., Feigin A., Dhawan V., et al. Dyskinesia after fetal cell transplantation for parkinsonism: a PET study. Ann Neurol 52 (2002) 628-634
185. Manson A.J., Schrag A., and Lees A.J. Low-dose olanzapine for levodopa induced dyskinesias. Neurology 55 (2000) 795-799
186. Manson A.J., Katzenschlager R., Hobart J., et al. High dose naltrexone for dyskinesias induced by levodopa. J Neurol Neurosurg Psychiatry 70 (2001) 554-556
187. Manson A.J., Turner K., and Lees A.J. Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: long-term follow-up study of 64 patients. Mov Disord 17 (2002) 1235-1241
188. Maratos E.C., Jackson M.J., Pearce R.K., et al. Antiparkinsonian activity and dyskinesia risk of ropinirole and L-DOPA combination therapy in drug naive MPTP-lesioned common marmosets. Mov Disord 16 (2001) 631-641
189. Marin C., Jimenez A., Tolosa E., et al. Bilateral subthalamic nucleus lesion reverses L-dopa-induced motor fluctuations and facilitates dyskinetic movements in hemiparkinsonian rats. Synapse 51 (2004) 140-150
190. Marek K., Jennings D., and Seibyl J. Do dopamine agonists or levodopa modify Parkinson's disease progression?. Eur J Neurol 9 Suppl 3 (2002) 15-22
191. Marsden C.D. The mysterious motor function of basal ganglia. Neurology 32 (1982) 514-539
192. Marsden C.D., and Obeso J.A. The functions of the basal ganglia and the paradox of stereotaxic surgery in Parkinson's disease. Brain 117 (1994) 877-897
193. Marsden C.D., and Parkes J. Success and problems of long-term levodopa therapy in Parkinson's disease. The Lancet 1 (1977) 345-349
194. Marsden C.D., Parkes J.S., and Quinn N.P. Fluctuations of disability in Parkinson's disease clinical aspects. In: Marsden C.D., and Fahn S. (Eds). Neurology 2: Movement Disorders (1981), Butterworth Scientific, London-New York 96-122
195. Martinez-Mir M.I., Probst A., and Palacios J.M. Adenosine A2 receptors: selective localization in the human basal ganglia and alterations with disease. Neurosci 42 (1991) 697-706
196. Massey P.V., Johnson B.E., Moult P.R., et al. Differential roles of NR2A and NR2B-containing NMDA receptors in cortical long-term potentiation and long-term depression. J Neurosci 24 (2004) 7821-7828
197. Meco G., Fabrizio E., Di Rezze S., et al. Mirtazapine in L-dopa-induced dyskinesias. Clin Neuropharmacol 26 (2003) 179-181
198. Meissner W., Ravenscroft P., Reese R., et al. Increased slow oscillatory activity in substantia nigra pars reticulata triggers abnormal involuntary movements in the 6-OHDA-lesioned rat in the presence of excessive extracellular striatal dopamine. Neurobiol Dis 22 (2006) 586-598
199. Menegoz M., Lau L.F., Herve D., et al. Tyrosine phosphorylation of NMDA receptor in rat striatum: effects of 6-OH-dopamine lesions. Neuroreport 7 (1995) 125-128
200. Merello M., Cammarota A., Betti O., et al. Involuntary movements during thermolesion predict a better outcome after microelectrode guided posteroventral pallidotomy. J Neurol Neurosurg Psychiatry 63 (1997) 210-213
201. Merello M., Balej J., Delfino M., et al. Apomorphine induces changes in GPi spontaneous outflow in patients with Parkinson's disease. Mov Disord 14 (1999) 45-49
202. Merello M., Nouzeilles M.I., Cammarota A., et al. Effect of memantine (NMDA antagonist) on Parkinson's disease: a double-blind crossover randomized study. Clin Neuropharmacol 22 (1999) 273-276
203. Merello M., Starkstein S., Nouzeilles M.I., et al. Bilateral pallidotomy for treatment of Parkinson's disease induced corticobulbar syndrome and psychic akinesia avoidable by globus pallidus lesion combined with contralateral stimulation. J Neurol Neurosurg Psychiatry 71 (2001) 611-614
204. Merello M., Perez Lloret S., Antico J., et al. Dyskinesias induced by subthalamotomy in Parkinson's disease are unresponsive to amantadine. J Neurol Neurosurg Psychiatry 77 (2006) 172-174
205. Meshul C.K., Emre N., Nakamura C.M., et al. Time-dependent changes in striatal glutamate synapses following a 6-hydroxydopamine lesion. Neurosci 88 (1999) 1-16
206. Miller D.W., and Abercrombie E.D. Role of high-affinity dopamine uptake and impulse activity in the appearance of extracellular dopamine in striatum after administration of exogenous L-DOPA: studies in intact and 6-hydroxydopamine-treated rats. J Neurochem 72 (1999) 1516-1522
207. Mink J.W. The basal ganglia and involuntary movements: impaired inhibition of competing motor patterns. Arch Neurol 60 (2003) 1365-1368
208. Mink J.W., and Thach W.T. Basal ganglia motor control III. Pallidal ablation: normal reaction time, muscle contraction, and slow movement. J Neurophysiol 65 (1991) 330-351
209. Mitchell I.J., Jackson A., Sambrook M.A., et al. The role of the subthalamic nucleus in experimental chorea. Evidence from 2-deoxyglucose metabolic mapping and horseradish peroxidase tracing studies. Brain 112 (1989) 1533-1548
210. Mitchell I.J., Boyce S., Sambrook M.A., et al. A 2-deoxyglucose study of the effects of dopamine agonists on the parkinsonian primate brain. Implications for the neural mechanisms that mediate dopamine agonist-induced dyskinesias. Brain 115 (1992) 808-824
211. Molinuevo J., Valldeoriola F., Tolosa E., et al. Levodopa withdrawal alter bilateral subthalamic nucleus stimulation in advanced Parkinson's disease. Arch Neurol 57 (2000) 983-988
212. Monyer H., Sprengel R., Schoepfer R., et al. Heteromeric NMDA receptors: molecular and functional distinction of subtypes. Science 256 (1992) 1217-1221
213. Morissette M., Goulet M., Soghomonian J.J., et al. Preproenkephalin mRNA expression in the caudate-putamen of MPTP monkeys after chronic treatment with the D2 agonist U91356A in continuous or intermittent mode of administration: comparison with L-DOPA therapy. Brain Res Mol Brain Res 49 (1997) 55-62
214. Morissette M., Goulet M., Grondin R., et al. Associative and limbic regions of monkey striatum express high levels of dopamine D3 receptors: effects of MPTP and dopamine agonist replacement therapies. Eur J Neurosci 10 (1998) 2565-2573
215. Morissette M., Dridi M., Calon F., et al. Prevention of dyskinesia by an NMDA receptor antagonist in MPTP monkeys: effect on adenosine A2A receptors. Synapse 60 (2006) 239-250
216. Moro E., Scerrati M., Romito L.M., et al. Chronic subthalamic stimulation requirements in Parkinson's disease. Neurology 53 (1999) 85-90
217. Moro E., Esselink R., Benabid A.L., et al. Response to levodopa in parkinsonian patients with bilateral subthalamic nucleus stimulation. Brain 125 (2002) 2408-2417
218. Mouradian M.M., Heuser I.J., Baronti F., et al. Modification of central dopaminergic mechanisms by continuous levodopa therapy for advanced Parkinson's disease. Ann Neurol 27 (1990) 18-23
219. Muenter M.D., Sharpless N.S., Tyce G.M., et al. Patterns of dystonia ("I-D-I" and "D-I-D") in response to L-dopa therapy of Parkinson's disease. Mayo Clinic Proc 52 (1977) 163-174
220. Murray T.K., Messenger M.J., Ward M.A., et al. Evaluation of the mGluR2/3 agonist LY379268 in rodent models of Parkinson's disease. Pharmacol Biochem Behav 73 (2002) 455-466
221. Narabayashi H., Yokochi F., and Nakajima Y. Levodopa-induced dyskinesia and thalamotomy. J Neurol Neurosurg Psychiatry 47 (1984) 831-839
222. Nisbet A.P., Foster O.J., and Kingsbury A. Preproenkephalin and preprotachykinin messenger mRNA expression in normal human basal ganglia and in Parkinson's disease. Neuroscience 66 (1995) 361-376
223. Nyholm D., Nilsson Remahl A.I., Dizdar N., et al. Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease. Neurology 64 (2005) 216-223
224. Obeso J.A., Luquin M.R., and Martinez-Lage J.M. Lisuride infusion pump: a device for the treatment of Parkinson's disease. Lancet 1 (1986) 467-470
225. Obeso J.A., Grandas F., Vaamonde J., et al. Motor complications associated with chronic levodopa therapy in Parkinson's disease. Neurology 39 Suppl 2 (1989) 11-18
226. Obeso J.A., Grandas F., Herrero M.T., et al. The role of pulsatile versus continous dopamine receptor stimulation for functional recovery in Parkinson's disease. Eur J Neurosci 6 (1994) 889-897
227. Obeso J.A., Rodriguez M.C., and DeLong M.R. Basal ganglia pathophysiology. A critical review. Adv Neurol 74 (1997) 3-18
228. Obeso J.A., Rodriguez-Oroz M.C., Rodriguez M., et al. Pathophysiology of the basal ganglia in Parkinson's disease. Trends Neurosci 23 10 Suppl (2000) S8-S19
229. Obeso J.A., Rodríguez-Oroz M.C., Rodríguez M., et al. Current problems in understanding the basal ganglia model for Parkinson's disease and levodopa-induced dyskinesias. Ann Neurol 47 Suppl 1 (2000) 22-32
230. Obeso J.A., Olanow C.W., Rodriguez-Oroz M.C., et al. Deep Brain Stimulation for Parkinson's Disease Study Group. Deep brain stimulation of the subthalamic nucleus or the pars interna of the globus pallidus in Parkinson's disease. N Engl J Med 345 (2001) 956-963
231. Obeso J.A., Rodriguez-Oroz M., Marin C., et al. The origin of motor fluctuations in Parkinson's disease: importance of dopaminergic innervation and basal ganglia circuits. Neurology 62 Suppl 1 (2004) S17-S30
232. Oh J.D., Del Dotto P., and Chase T.N. Protein kinase A inhibitor attenuates levodopa-induced motor response alterations in the hemi-parkinsonian rat. Neurosci Lett 228 (1997) 5-8
233. Oh J.D., Bibbiani F., and Chase T.N. Quetiapine attenuates levodopa-induced motor complications in rodent and primate parkinsonian models. Exp Neurol 177 (2002) 557-564
234. Ohye C., Maeda T., and Narabayashi H. Physiologically defined Vim nucleus, its special reference to the control of tremor. Appl Neurophysiol 39 (1976) 285-295
235. Olanow C.W., Goetz C.G., Kordower J.H., et al. A double blind placebo-controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann Neurol 54 (2003) 403-414
236. Page R.D., Sambrook M.A., and Crossman A.R. Thalamotomy for the alleviation of levodopa-induced dyskinesia: experimental studies in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treated parkinsonian monkey. Neurosci 55 (1993) 147-165
237. Papa S.M., and Chase T.N. Levodopa-induced dyskinesias improved by a glutamate antagonist in Parkinsonian monkeys. Ann Neurol 39 (1996) 574-578
238. Papa S.M., Desimone R., Fiorani M., et al. Internal globus pallidus discharge is nearly suppressed during levodopa-induced dyskinesias. Ann Neurol 46 (1999) 732-738
239. Patel N., Plaha P., O'Sullivan K., et al. MRI directed bilateral stimulation of the subthalamic nucleus in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 74 (2003) 1631-1637
240. Piccini P., Weeks R.A., and Brooks D.J. Alterations in opioid receptor binding in Parkinson's disease patients with levodopa-induced dyskinesias. Ann Neurol 42 (1997) 720-726
241. Picconi B., Pisani A., Centonze D., et al. Striatal metabotropic glutamate receptor function following experimental parkinsonism and chronic levodopa treatment. Brain 125 (2002) 2635-2645
242. Picconi B., Centonze D., Hakansson K., et al. Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia. Nat Neurosci 6 (2003) 501-506
243. Picconi B., Gardoni F., Centonze D., et al. Abnormal Ca2+-calmodulin-dependent protein kinase II function mediates synaptic and motor deficits in experimental parkinsonism. J Neurosci 24 (2004) 5283-5291
244. Pinna A., Corsi C., Carta A.R., et al. Modification of adenosine extracellular levels and adenosine A (2A) receptor mRNA by dopamine denervation. Eur J Pharmacol 446 (2002) 75-82
245. Pinna A., Wardas J., Simola N., et al. New therapies for the treatment of Parkinson's disease: Adenosine A (2A) receptor antagonists. Life Sci 77 (2005) 3259-3267
246. Pirtosek Z., Merello M., Carlsson A., et al. Preclamol and parkinsonian fluctuations. Clin Neuropharmacol 16 (1993) 550-554
247. Pisani A., Bonsi P., Catania M.V., et al. Metabotropic glutamate 2 receptors modulate synaptic inputs and calcium signals in striatal cholinergic interneurons. J Neurosci 22 (2002) 6176-6185
248. Pisani A., Centonze D., Bernardi G., et al. Striatal synaptic plasticity: implications for motor learning and Parkinson's disease. Mov Disord 20 (2005) 395-402
249. Quik M., Police S., He L., et al. Expression of D(3) receptor messenger RNA and binding sites in monkey striatum and substantia nigra after nigrostriatal degeneration: effect of levodopa treatment. Neurosci 98 (2000) 263-273
250. Quik M., Police S., Langston J.W., et al. Increases in striatal preproenkephalin gene expression are associated with nigrostriatal damage but not L-DOPA-induced dyskinesias in the squirrel monkey. Neurosci 113 (2002) 213-220
251. Rabiner E.A., Gunn R.N., Wilkins M.R., et al. Evaluation of EMD128130 occupancy of the 5HT1A and the D2 receptor: a human PET study with [11C]WAY-100365 and [11C]-raclopride. J Psychopharmacol 16 (2002) 195-199
252. Rascol O., Fabre N., Blin O., et al. Naltrexone, an opiate antagonist, fails to modify motor symptoms in patients with Parkinson's disease. Mov Disord 9 (1994) 437-440
253. Rascol O., Sabatini U., Brefel C., et al. Cortical motor overactivation in parkinsonian patients with L-Dopa induced peak-dose dyskinesia. Brain 121 (1998) 527-533
254. Rascol O., Brooks D.J., Korczyn A.D., et al. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med 342 (2000) 1484-1491
255. Rascol O., Arnulf I., Peyro-Saint Paul H., et al. Idazoxan, an alpha-2 antagonist, and L-DOPA-induced dyskinesias in patients with Parkinson's disease. Mov Disord 16 (2001) 708-713
256. Robertson R.G., Farmery S.M., Sambrook M.A., et al. Dyskinesia in the primate following injection of an excitatory amino acid antagonist into the medial segment of the globus pallidus. Brain Res 476 (1989) 317-322
257. Rodriguez-Oroz M.R., Obeso J.A., Lang A.E., et al. Bilateral deep brain stimulation in Parkinson's disease: a multicentre study with 4 years follow-up. Brain 128 (2005) 2240-2249
258. Samadi P., Gregoire L., and Bedard P.J. The opioid agonist morphine decreases the dyskinetic response to dopaminergic agents in parkinsonian monkeys. Neurobiol Dis 16 (2004) 246-253
259. Samuel M., Ceballos Boumann A.O., Turjanski N., et al. Pallidotomy in Parkinson's disease increases supplementary motor area and prefrontal activation during performance of volitional movements. An H2O PET study. Brain 12 (1997) 1301-1313
260. Sandyk R., and Snider S.N. Naloxone treatment of L-Dopa-induced dyskinesias in Parkinson's disease. Am J Psychiatry 143 (1986) 118
261. Santiago M., Matarredona E.R., Machado A., et al. Influence of serotoninergic drugs on in vivo dopamine extracellular output in rat striatum. J Neurosci Res 52 (1998) 591-598
262. Shinotoh H., Hirayama K., and Tateno Y. Dopamine D1 and D2 receptors in Parkinson's disease and striatonigral degeneration determined by PET. Adv Neurol 60 (1993) 488-493
263. Shoulson I. DATATOP: a decade of neuroprotective inquiry. Parkinson Study Group. Deprenyl And Tocopherol Antioxidative Therapy Of Parkinsonism. Ann Neurol 44 Suppl 1 (1998) S160-S166
264. Silberstein P., Kuhn A.A., Kupsch A., et al. Patterning of globus pallidus local field potentials differs between Parkinson's disease and dystonia. Brain 126 (2003) 2597-2608
265. Silverdale M.A., Crossman A.R., and Brotchie J.M. Striatal AMPA receptor binding is unaltered in the MPTP-lesioned macaque model of Parkinson's disease and dyskinesia. Exp Neurol 174 (2002) 21-28
266. Simuni T., Jaggi J.L., Mulholland H., et al. Bilateral stimulation of the subthalamic nucleus in patients with Parkinson's disease: a study of efficacy and safety. J Neurosurg 96 (2002) 666-672
267. Smith Y., Charara A., and Parent A. Synaptic innervation of midbrain dopaminergic neurons by glutamate-enriched terminals in the squirrel monkey. J Comp Neurol 364 (1996) 231-253
268. Snow B.J., Macdonald L., Mcauley D., et al. The effect of amantadine on levodopa-induced dyskinesias in Parkinson's disease: a double-blind, placebo-controlled study. Clin Neuropharmacol 23 (2000) 82-85
269. Sokoloff P., Giros B., Martres M.P., et al. Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature 347 (1990) 146-151
270. Standaert D.G., Testa C.M., Penney J.B., et al. Organization of N-methyl-D-aspartate glutamate receptor gene expression in the basal ganglia of the rat. J Comp Neurol 64 (1994) 11-23
271. Stanford I.M., Kantaria M.A., Chahal H.S., et al. 5-Hydroxytryptamine induced excitation and inhibition in the subthalamic nucleus: action at 5-HT2c, 5-HTA4 and 5-HT1A receptors. Neuropharmacology 49 (2005) 1228-1234
272. Steiner H., and Gerfen C.R. Enkephalin regulates acute D2 dopamine receptor antagonist-induced immediate early gene expression in striatal neurons. Neurosci 88 (1999) 795-810
273. Stephens B., Mueller A.J., Shering A.F., et al. Evidence of a breakdown of corticostriatal connections in Parkinson's disease. Neurosci 132 (2005) 741-754
274. Stocchi F., Ruggieri S., Vacca L., et al. Prospective randomized trial of lisuride infusion versus oral levodopa in patients with Parkinson's disease. Brain 125 (2002) 2058-2066
275. Su P., Tseng H.M., Liu H.M., et al. Subthalamotomy for advanced Parkinson's disease. J Neurosurg 97 (2002) 598-606
276. Sung K.W., Choi S., and Lovinger D.M. Activation of group ImGluRs is necessary for long-term depression in striatal synapses. J Neurophysiol 86 (2001) 2405-2412
277. Svenningsson P., Le Moine C., Aubert I., et al. Cellular distribution of adenosine A2A receptor mRNA in the primate striatum. J Comp Neurol 399 (1998) 299 240
278. Swope S.L., Moss S.J., Raymond L.A., et al. Regulation of ligand-gated ion channels by protein phosphorylation. Adv Second Messenger Phosphoprotein Res 33 (1999) 49-78
279. Tanaka H., Kannari K., Maeda T., et al. Role of serotoninergic neurons in L-Dopa derived extracellular dopamine in the striatum of 6-OHDA-lesioned rats. Neuroreport 10 (1999) 631-634
280. Tasker R.R. Thalamotomy. Neurosurg Clin N Am 1 (1990) 841-864
281. Tasker R.R., Munz M., Junn F.S.C.K., et al. Deep brain stimulation and thalamotomy for tremor compared. Acta Neurochir Suppl 68 (1997) 49-53
282. Tekumalla P.K., Calon F., Rahman Z., et al. Elevated levels of DeltaFosB and RGS9 in striatum in Parkinson's disease. Biol Psychiatr 50 (2001) 813-816
283. Tel B.C., Zeng B.Y., Cannizzaro C., et al. Alterations in striatal neuropeptide mRNA produced by repeated administration of L-Dopa, ropinirole or bromocriptine correlate with dyskinesia induction on MPTP-treated common marmosets. Neuroscience 115 (2002) 1047-1058
284. Thomas A., Iacono D., Luciano A.L., et al. Duration of amantadine benefit on dyskinesia of severe Parkinson's disease. J Neurol Neurosurg Psychiatry 75 (2004) 141-143
285. Tomiyama M., Kimura T., Maeda T., et al. A serotonin 5-HT1A receptor agonist prevents behavioral sensitization to levodopa in a rodent model of Parkinson's disease. Neurosci Res 52 (2005) 185-194
286. Touchon J.C., Moore C., Frederickson C., et al. Lesion of subthalamic or motor thalamic nucleus in 6-hydroxydopamine-treated rats: effects on striatal glutamate and apomorphine-induced contralateral rotations. Synapse 15 (2004) 287-298
287. Trabucchi M., Bassi S., and Frattola L. Effect of naloxone on the "on-off" syndrome in patients receiving long-term levodopa therapy. Arch Neurol 39 (1982) 120-121
288. Ulas J., Weihmuller F.B., Brunner L.C., et al. Selective increase of NMDA-sensitive glutamate binding in the striatum of Parkinson's disease, Alzheimer's disease, and mixed Parkinson's disease/Alzheimer's disease patients: an autoradiographic study. J Neurosci 14 (1994) 6317-6324
289. Vaamonde J., Luquin M.R., and Obeso J.A. Subcutaneous lisuride infusion in Parkinson's disease: response to chronic administration in 34 patients. Brain 114 (1991) 601-614
290. Verhagen Metman L., Del Dotto P., Blanchet P.J., et al. Blockade of glutamatergic transmission as treatment for dyskinesias and motor fluctuations in Parkinson's disease. Amino Acids 14 (1998) 75-82
291. Verhagen Metman L., Del Dotto P., Natte R., et al. Dextromethorphan improves levodopa-induced dyskinesias in Parkinson's disease. Neurology 51 (1998) 203-206
292. Vila M., Levy R., Herrero M.T., et al. Consequences of nigrostriatal denervation on the functioning of the basal ganglia in human and nonhuman primates: an in situ hybridization study of cytochrome oxidase subunit I mRNA. J Neurosci 17 (1997) 765-773
293. Vingerhoets F.J.G., Villemure J.G., Temperli P., et al. Subthalamic DBS replace levodopa in Parkinson's disease: two year follow-up. Neurology 58 (2002) 396-401
294. Visser-Vanderwalle V., Van der Linden C., Temel Y., et al. Long term motor effect of unilateral pallidal stimulation in 26 patients with advanced Parkinson disease. J Neurosurg 99 (2003) 701-707
295. Vitek J.L., and Giroux M. Physiology of hypokinetic and hyperkinetic movement disorders: model for dyskinesia. Ann Neurol 47 Suppl 1 (2000) S131-S140
296. Vitek J.L., Chockkan V., Zhang I.Y., et al. Neuronal activity in the basal ganglia in patients with generalized dystonia and hemiballismus. Ann Neurol 46 (1999) 22-35
297. Volkmann J., Allert N., Voges J., et al. Long term results of bilateral pallidal stimulation in Parkinson's disease. Ann Neurol 55 (2004) 871-875
298. Whittier J.R., and Mettler F.A. Studies of the subthalamus in rhesus monkey. II. Hyperkinesia and other physiological effects of the subthalamic lesion, with special reference to the subthalamic nucleus of Luys. J Comp Neurol 90 (1949) 319-372
299. Whone A.L., Watts R.L., Stoessl A.J., et al. REAL-PET Study Group. Slower progression of Parkinson's disease with ropinirole versus levodopa: the REAL-PET study. Ann Neurol 54 (2003) 93-101
300. Yelnik J., Damier P., Demeret S., et al. Localization of stimulation electrodes in patients with Parkinson disease by using a three-dimensional atlas-magnetic resonance coregistration method. J Neurosurg 99 (2003) 89-99
301. Zeng B.Y., Pearce R.K., MacKenzie G.M., et al. Alterations in preproenkephalin and adenosine-2a receptor mRNA, but not preprotachykinin mRNA correlate with occurrence of dyskinesia in normal monkeys chronically treated with L-DOPA. Eur J Neurosci 12 (2000) 1096-1104